AIRLINK 204.45 Increased By ▲ 3.55 (1.77%)
BOP 10.09 Decreased By ▼ -0.06 (-0.59%)
CNERGY 6.91 Increased By ▲ 0.03 (0.44%)
FCCL 34.83 Increased By ▲ 0.74 (2.17%)
FFL 17.21 Increased By ▲ 0.23 (1.35%)
FLYNG 24.52 Increased By ▲ 0.48 (2%)
HUBC 137.40 Increased By ▲ 5.70 (4.33%)
HUMNL 13.82 Increased By ▲ 0.06 (0.44%)
KEL 4.91 Increased By ▲ 0.10 (2.08%)
KOSM 6.70 No Change ▼ 0.00 (0%)
MLCF 44.31 Increased By ▲ 0.98 (2.26%)
OGDC 221.91 Increased By ▲ 3.16 (1.44%)
PACE 7.09 Increased By ▲ 0.11 (1.58%)
PAEL 42.97 Increased By ▲ 1.43 (3.44%)
PIAHCLA 17.08 Increased By ▲ 0.01 (0.06%)
PIBTL 8.59 Decreased By ▼ -0.06 (-0.69%)
POWER 9.02 Decreased By ▼ -0.09 (-0.99%)
PPL 190.60 Increased By ▲ 3.48 (1.86%)
PRL 43.04 Increased By ▲ 0.98 (2.33%)
PTC 25.04 Increased By ▲ 0.05 (0.2%)
SEARL 106.41 Increased By ▲ 6.11 (6.09%)
SILK 1.02 Increased By ▲ 0.01 (0.99%)
SSGC 42.91 Increased By ▲ 0.58 (1.37%)
SYM 18.31 Increased By ▲ 0.33 (1.84%)
TELE 9.14 Increased By ▲ 0.03 (0.33%)
TPLP 13.11 Increased By ▲ 0.18 (1.39%)
TRG 68.13 Decreased By ▼ -0.22 (-0.32%)
WAVESAPP 10.24 Decreased By ▼ -0.05 (-0.49%)
WTL 1.87 Increased By ▲ 0.01 (0.54%)
YOUW 4.09 Decreased By ▼ -0.04 (-0.97%)
BR100 12,137 Increased By 188.4 (1.58%)
BR30 37,146 Increased By 778.3 (2.14%)
KSE100 115,272 Increased By 1435.3 (1.26%)
KSE30 36,311 Increased By 549.3 (1.54%)

GENEVA: WHO experts warned Tuesday that repeating booster doses of the original Covid vaccines is not a viable strategy against emerging variants and called for new jabs that better protect against transmission.

An expert group created by the World Health Organization to assess the performance of Covid-19 vaccines said simply providing fresh jabs of existing Covid vaccines as new strains of the virus emerge was not the best way to fight the pandemic.

"A vaccination strategy based on repeated booster doses of the original vaccine composition is unlikely to be appropriate or sustainable," the WHO Technical Advisory Group on Covid-19 Vaccine Composition (TAG-Co-VAC) said in a statement.

It said preliminary data indicated the existing vaccines were less effective at preventing symptomatic Covid disease in people who have contracted the new Omicron variant, currently spreading like wildfire around the world.

Merck expects COVID-19 pill molnupiravir to be effective against Omicron

But protection against severe disease, which is what the jabs were especially intended to do, "is more likely to be preserved".

It recommended developing vaccines that not only protect people against falling seriously ill but could also better prevent infection and transmission in the first place.

"Covid-19 vaccines that have high impact on prevention of infection and transmission, in addition to the prevention of severe disease and death, are needed and should be developed," TAG-Co-VAC said.

"Until such vaccines are available, and as the SARS-CoV-2 virus evolves, the composition of current Covid-19 vaccines may need to be updated, to ensure that (they) continue to provide WHO-recommended levels of protection against infection and disease by VOCs (variants of concern), including Omicron and future variants."

Comments

Comments are closed.